CXCR5 and neoplasm: CXCL13+ T cells have also been upregulated in other tumors responsive to immunotherapy[21] and are positively correlated with tumor neoantigen reactivity.[18] These cells secrete CXCL13, which targets CXCR5 on NR4A2+ B cells and may promote TLS formation.